Under the Adverse Drug Reactions Information Scheme (ADRIS) data and knowledge relevant to the etiology of adverse drug reactions (ADRs) such as chemical structure of parent compounds, metabolites, covalent adducts, nucleic acid and protein sequences, protein structures, pharmaco-, toxico-and enzyme kinetics, pharmaco-and toxicodynamics, protein interactions, molecular pathways and complexes, as well as toxicological and clinical outcomes, are collected and logically and semantically related. ADRIS reflects the ontological prerequisite for the creation of databases and knowledge discovery systems for the abstraction and visualization of theragenomic concepts. A final outcome is the prediction of ADRs based on a profound knowledge of drug function and the molecular basics for personalized drug safety and eventually, personalized medicine. Pharmacogenetics
Introduction
The person-to-person variability of a drug response is a major problem in clinical practice and in drug development [1] . It can lead to both adverse drug reactions (ADRs) of drugs or to therapeutic failure in individual patients or in sub-populations of patients. The occurrence of serious or fatal ADRs has been extensively analyzed in hospital inpatients [2] . A meta-analysis of about 40 prospective studies from hospitals in the USA suggests that 6 to 7% of inpatients suffer from serious ADRs and 0.32% of patients have fatal ADRs. This results in about 100 000 deaths per year in the USA. This figure makes fatal ADRs between the fourth and sixth leading cause of death in hospital inpatients.
ADRs can be classified in terms of their clinical, pharmacological, and chemical characteristics. From a clinical point of view, ADRs may comprise type A and type B reactions. Type A or augmented reactions can be predicted from the known pharmacology and often represent an exaggeration of the pharmacological effects of the drug. These reactions are usually dose dependent and may be reversed by dose reduction. Examples of type A reactions include hypotension with antihypertensives and hemorrhage with anticoagulants. Type B or bizarre (idiosyncratic) reactions cannot be predicted from a knowledge of the basic pharmacology of the drug and have no simple dose response relationship, that is, there is a lack of correlation between dose and risk of toxicity. Host-dependent factors seem to be important in predisposition to these reactions, although for most forms of idiosyncratic drug reactions, these factors have not been elucidated. Such reactions are thought to have both metabolic and immunological components that may determine individual susceptibility. These reactions tend to be serious and account for many drug-induced deaths. Examples of type B reactions include halothane-induced hepatitis [3] and anticonvulsant hypersensitivity [4] .
From a chemical (i.e., structural) point of view, ADRs may comprise type C and type D reactions. Type C or chemical reactions are those reactions whose biological characteristics can be either rationalized or even predicted based on the chemical structure of the parent drug, or of reactive intermediates and metabolites thereof. A classic example of a type C reaction is the hepatotoxicity caused by high doses of acetaminophen. Type D or delayed reactions may occur many years after treatment such as, for example, secondary tumors which appear years after treatment with chemotherapeutic agents. Also included in this category of ADRs are teratogenic effects seen in children after drug intake by the mother during pregnancy, such as, for example, in the fetal hydantoin syndrome with phenytoin [5] .
The collection of data related to ADRs is tedious. Relevant data and knowledge are dispersed in a variety of databases in non-compatible formats. Furthermore, a huge amount of new ADR data is created in the postgenomic area, for example single nucleotide polymorphisms (SNPs), splice variants, gene expression, etc. Therefore, we developed the Adverse Drug Reac-tions Information Scheme (ADRIS) to conceptionally organize and relate heterogeneous data such as chemical structures, nucleic acid and protein sequence information, protein structure, genetic data, metabolites, covalent adducts, pharmacokinetics, toxicokinetics, metabolic pathways, enzyme kinetics, pharmacodynamics, toxicodynamics, protein interactions, molecular complexes, molecular pathways and toxicological and clinical outcomes. Based on this data research focuses on knowledge management and visualization of theragenomic concepts, which allows integration of diverse data ranging from chemical structures to patient related data. ADRIS is the conceptional basis (i.e. ontology and architecture) for data and knowledge allowing a holistic view on ADRs, which can be realized in intelligent knowledge management and discovery systems such as, for example, SafeBase. While at the moment SafeBase is a commercial product, efforts are in place to make it freely accessible to scientists in the academic community through co-operations and collaborations.
Databases, theragenomic knowledge management and visualization
The main concept behind ADRIS is the conceptional organization and the according linkage of diverse yet related data. In ADRIS information is abstracted in an object oriented way and consists of discrete defined entities such as genes, proteins, chemical structures, covalent adducts, individuals, processes etc., that can be annotated with predefined properties in various formats such as, for example, synonyms, sequences, domains, V max , C max , Chemical Abstracts Service (CAS) number, etc.
All data entities can be semantically related to other entities within the scheme. ADRIS was conceptually inspired by the idea of TopicMaps (http://www.topicmaps. org/) but is not a TopicMaps implementation. None of the current biological database systems provides an information scope compared to what is handled with ADRIS, since they mostly focus on a single property (e.g., sequence, structure, alleles, literature, etc.), and do not semantically relate the single pieces of data. A significant improvement in ADRIS is the inclusion of the semantic linkages. The information content of a typical implementation of ADRIS in database systems such as SafeBase knowledge base is constantly increasing; currently it contains over 15 000 data objects, over 20 000 relations, over 300 concepts and over 110 000 properties, including data on chemical structures, metabolites, covalent adducts, etc.
Within ADRIS actual data and meta-data (i.e., information that describes the actual data), are integrated in one system to efficiently organize and query ADRrelated information. Therefore, unlike other data sources that mainly contain links to external data repositories, ADRIS handles the relevant data locally as well as links pointing to the original data source. Also data derived from automatic computation such as Simplified Molecular Input Line Entry System (SMILES), chemical sum formula or the molecular weight for a chemical structure can be manipulated. Therefore, data can be mined in one ontologically integrated system to gain further knowledge about drug metabolism and function. Knowledge and data are derived from public databases, publications and through co-operations with basic and clinical research groups.
Nucleic acid and protein sequence information is mainly obtained and edited from public databases such as NCBI (http://www.ncbi.nlm.nih.gov/), EMBL Nucleotide Sequence Database (http://www.ebi.ac.uk/ embl/) [6] , or SWISS-PROT [7, 8] , respectively. The naming of genes and proteins follows the Gene Ontology Consortium [9] . Allelic variants are derived and edited from the literature, the Human Gene Mutation Database (HGMD) [10] and the Online Mendelian Inheritance in Man (OMIM) database (http://www. ncbi.nlm.nih.gov/omim/). Whenever possible the data on genes, proteins, allelic variants, metabolites, drugs, pharmacokinetics and dynamics are connected to known clinical endpoints. Finally, ADRIS allows the integration and handling of data about individual patients. Patient data that is relevant to the etiology of ADRs is decoupled from the patient's name and from patient data that could lead to an identification of a single patient. Ethical issues are regulated through the EU guidelines. Together, this is an important step towards personalized drug safety and eventually personalized medicine. Figures 1 and 2 highlight an example of how theragenomic data may be handled by databases/knowledge management systems, which are based on ADRIS, such as SafeBase. Figure 1 shows a possible graphical representation of the relations of allelic and protein variants, using CYP2C9 as an example. Figure 2 shows the excerpt of a theragenomic concept centered around the metabolic pathway of diclofenac (A) and meclofenamic acid (B) in humans. Generally, data objects (genes, proteins, chemical structures, clinical endpoints, etc.) are visualized as circular icons when they contain general information and as rectangular icons when they contain specific information.
Each data object may contain detailed properties related to that object. The representation and the inclusion of extended sets of properties enables the data to be mined to obtain the answer to a variety of questions such as, does meclofenamic acid act as a substrate of CYP2C9? Does meclofenamic acid, based on its chemical similarity to diclofenac, induce ADRs similar to those induced by diclofenac? Such questions will help in the design of experiments and studies in differential risk assessment at all stages of the drug development process.
Other systems are also conceivable. Thus a similar approach is taken by the PharmGKB Community Submission Project [11] , which collects pharmacogenetic information via web submission. However, with respect to web submissions, we have the experience that extensive revision, filtering, editing and reformatting of such data by scientists specialized in the Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
CYP2C9.2
The CYP2C9.2 variant has slower rates of metabolism for the hydroxylations of the 3 substrate (S)-warfarin (7-OH), diclofenac (4'-OH) and lauric acid (11-OH) than the wt [14] Creation of a cysteine-might be a new site for disulfide formation R144C [14, 15] Fig. 1 Graphical representation of the ADRIS-based ontological relations of allelic and protein variants of CYP2C9 in SafeBase. Allelic and protein variants of CYP2C9 are visualized as rectangular data objects (specific information), which are connected to circular generic data objects. The available specific information for the allelic variant CYP2C9 Ã 2 and the protein variant CYP2C9.2 is shown. (a) Fig. 2 Excerpt of a theragenomic concept centered around the metabolic pathway of diclofenac in humans. (A) Visualization of known metabolic pathways and ADRs of diclofenac generated by using the tool 'find neighbors'. The starting data object was CYP2C9. Data objects can be easily added or removed. Pharmacokinetic data of a hydroxylation reaction and the specific information of diclofenac, which are obtained by double clicking the data objects kinetics and diclofenac respectively, are included. (B) Meclofenamic acid is analyzed for ADRs because it has a relatively high structural similarity to diclofenac. The ontological relations to its metabolic pathways, to intended therapies, and to possible ADRs are visualized.
respective fields is necessary to assure and maintain a high quality and consistency of data and to make them amenable for the required manipulations under ADRIS. Moreover, such systems lack the intuitive usability of their interface and the clear visualization of relations between data objects and of whole theragenomic concepts.
Efforts are undertaken to make ADRIS available to scientists in the academic field who wish to use it in joint projects or who are members of co-operations through networks in the public domain.
Future developments
The advantages and strengths of ADRIS are the handling of diverse data. The conceptual improvement of ADRIS is to display all aspects of drug safety. In areas such as intracellular signal transduction pathways, protein-protein, protein-ligand, protein-DNA and protein-drug interactions and drug-induced autoimmunity ADRIS will be expanded. Helpful information is contained in databases such as, for example, the Biomolecular Interaction Network Database (BIND), which has data on interactions of proteins, nucleic acids and small molecules, complexes and signal transduction pathways [12] , the Database of Interacting Proteins (DIP) [13] , and others (http://www.hgmp.mrc.ac.uk/GenomeWeb/ prot-interaction.html). However, the vast majority of protein interaction data in BIND and DIP is from yeast, while human data are currently sparse.
In contrast to these protein interaction databases, ADRIS will concentrate on signal transduction and biomolecular interaction in pathways relevant to human disease and ADRs gathers data about pathways involved in regulation of transcription from different organisms. When integrated into a suitable front end, one major aspect of ADRIS in comparison to the other systems is that it not only connects metadata, but imports and stores metadata to act on them directly. However, BIND, DIP, TRANS-FAC, etc. could be valuable tools for systems that implement ADRIS, such as SafeBase, regarding pathway comparison and supplementary information to human signal transduction pathways, which play a major role in diseases.
ADRIS is further expanded to connect single nucleotide polymorphisms (SNP) to individuals in order to predict ADR profiles. This data is then correlated with the probable individual drug response. This is the prerequisite for personalized drug safety and medicine.
